TILRAY BRANDS INC (TLRY)
US88688T1007 - Common Stock
TLRY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TLRY have multiple concerns. TLRY is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TLRY had negative earnings in the past year.
TLRY had a negative operating cash flow in the past year.
In the past 5 years TLRY always reported negative net income.
TLRY had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TLRY has a Return On Assets of -4.99%. This is in the better half of the industry: TLRY outperforms 78.01% of its industry peers.
Looking at the Return On Equity, with a value of -6.11%, TLRY belongs to the top of the industry, outperforming 80.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.99% | ||
| ROE | -6.11% | ||
| ROIC | N/A |
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 29.41%, TLRY perfoms like the industry average, outperforming 54.45% of the companies in the same industry.
TLRY's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TLRY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
2. Health
2.1 Basic Checks
TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
The number of shares outstanding for TLRY has been increased compared to 5 years ago.
The debt/assets ratio for TLRY has been reduced compared to a year ago.
2.2 Solvency
TLRY has an Altman-Z score of 0.15. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
TLRY has a Altman-Z score (0.15) which is in line with its industry peers.
TLRY has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
TLRY has a Debt to Equity ratio (0.10) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.15 |
ROIC/WACCN/A
WACC9.11%
2.3 Liquidity
TLRY has a Current Ratio of 2.47. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
TLRY's Current ratio of 2.47 is in line compared to the rest of the industry. TLRY outperforms 45.03% of its industry peers.
TLRY has a Quick Ratio of 1.57. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
TLRY's Quick ratio of 1.57 is on the low side compared to the rest of the industry. TLRY is outperformed by 61.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.57 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 91.15% over the past year.
The Revenue has grown by 24.78% in the past year. This is a very strong growth!
The Revenue has been growing by 78.86% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)91.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)24.78%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%13.05%
3.2 Future
Based on estimates for the next years, TLRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.27% on average per year.
The Revenue is expected to grow by 8.96% on average over the next years. This is quite good.
EPS Next Y66%
EPS Next 2Y31.35%
EPS Next 3Y27.62%
EPS Next 5Y18.27%
Revenue Next Year15.56%
Revenue Next 2Y10.65%
Revenue Next 3Y9.96%
Revenue Next 5Y8.96%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
76.44% of the companies in the same industry are more expensive than TLRY, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 42.91 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TLRY's earnings are expected to grow with 27.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.35%
EPS Next 3Y27.62%
5. Dividend
5.1 Amount
TLRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TILRAY BRANDS INC
NASDAQ:TLRY (12/20/2024, 8:00:01 PM)
After market: 1.24 -0.02 (-1.59%)1.26
+0.1 (+8.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners10.39%
Inst Owner Change11.47%
Ins Owners7.91%
Ins Owner Change1.4%
Market Cap1.14B
Analysts72
Price Target2.29 (81.75%)
Short Float %12.11%
Short Ratio3.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.59%
Min EPS beat(2)-78.25%
Max EPS beat(2)-8.93%
EPS beat(4)1
Avg EPS beat(4)-30.62%
Min EPS beat(4)-135.29%
Max EPS beat(4)100%
EPS beat(8)1
Avg EPS beat(8)-427.13%
EPS beat(12)3
Avg EPS beat(12)-346.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.66%
Min Revenue beat(2)-10.57%
Max Revenue beat(2)-0.75%
Revenue beat(4)0
Avg Revenue beat(4)-5.23%
Min Revenue beat(4)-10.57%
Max Revenue beat(4)-0.75%
Revenue beat(8)1
Avg Revenue beat(8)-2.29%
Revenue beat(12)1
Avg Revenue beat(12)-3.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.1%
PT rev (3m)-6.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.11%
EPS NY rev (1m)-4.01%
EPS NY rev (3m)-0.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.86%
Revenue NY rev (1m)-1.1%
Revenue NY rev (3m)-1.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.33 | ||
| P/tB | 2.03 | ||
| EV/EBITDA | 42.91 |
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.9
BVpS3.85
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.99% | ||
| ROE | -6.11% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.42% | ||
| FCFM | N/A |
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
F-Score5
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 14.41 | ||
| Cap/Depr | 24.88% | ||
| Cap/Sales | 3.92% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.57 | ||
| Altman-Z | 0.15 |
F-Score5
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)20.35%
Cap/Depr(5y)159.29%
Cap/Sales(3y)4.15%
Cap/Sales(5y)16.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y66%
EPS Next 2Y31.35%
EPS Next 3Y27.62%
EPS Next 5Y18.27%
Revenue 1Y (TTM)24.78%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%13.05%
Revenue Next Year15.56%
Revenue Next 2Y10.65%
Revenue Next 3Y9.96%
Revenue Next 5Y8.96%
EBIT growth 1Y40.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year140.08%
EBIT Next 3Y39.11%
EBIT Next 5Y25.01%
FCF growth 1Y45.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.34%
OCF growth 3YN/A
OCF growth 5YN/A